Mouse BTLA Protein

B and T lymphocyte associated Protein Datasheet

BTLA Protein Product Information

• Synonym: BTLA
• Protein Construction: A DNA sequence encoding the mouse BTLA(Met1-Gly176) was expressed, fused with the Fc region of human IgG1 at the C-terminus.
• Source: Mouse
• Expression Host: Human Cells

BTLA Protein QC Testing

• Purity: > 90 % as determined by SDS-PAGE
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Glu 30
• Molecular Mass: The recombinant mouse BTLA /Fc is a disulfide-linked homodimer. The reduced monomer comprises 388 amino acids and has a predicted molecular mass of 437 kDa. The apparent molecular mass of the protein is approximately 57-62 kDa in SDS-PAGE under reducing conditions due to glycosylation.
• Formulation: Lyophilized from sterile PBS, pH7.4.
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: BTLA protein

BTLA Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

BTLA Protein Description

BTLA is a member of the immunoglobulin superfamily. It contains a single immunoglobulin (Ig) domain and is a receptor that relays inhibitory signals to suppress the immune response. BTLA is not expressed by naive T cells, but it is induced during activation and remains expressed on T helper type 1 (T(H)1) but not T(H)2 cells. BTLA is one of a growing number of inhibitory molecules that down-modulates immune responses. As such, reagents that regulate the binding of BTLA to its ligand or alter BTLA signaling have significant therapeutic promise. BTLA is a third inhibitory receptor on T lymphocytes with similarities to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1). Polymorphisms in BTLA gene have been associated with an increased risk of rheumatoid arthritis.

References

1. Fourcade J. et al., 2012, Cancer Res. 72 (4): 887-96.
2. Kojima R. et al., 2011, J Mol Biol. 413 (4): 762-72.
3. Oki M. et al., 2011, Clin Dev Immunol. 305656.